BioMachines Announces Acquisition and new Management
News Feb 06, 2006
Clearview Limited has announced that it has purchased BioMachines on Dec. 29, 2005. Sam Tetlow, founding partner of Clearview and a principal with Research Triangle Ventures, is now chairman of BioMachines.
He has named Tom Larrichio, formerly vice president of business development at TriVirix International, Inc., as BioMachines' chief executive officer.
"After a comprehensive review of the genomic and proteomics industry, we believe BioMachines is uniquely positioned to achieve excellent commercial results from its market-proven, proprietary products," said Tetlow.
"The company has deep scientific expertise and a pipeline of novel diagnostic tools that will have a meaningful impact to the work of leading drug discovery researchers, especially those working in the growing field of proteomics."
Tetlow said he selected Larrichio as BioMachines' new CEO because of his sales acumen, extensive management experience and life science knowledge.
He adds, "Tom has the requisite commercial expertise to take the company to the next level."
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018